ProfileGDS5678 / 1424831_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 84% 84% 85% 84% 86% 86% 85% 85% 83% 85% 83% 84% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5435286
GSM967853U87-EV human glioblastoma xenograft - Control 26.3151984
GSM967854U87-EV human glioblastoma xenograft - Control 36.2096284
GSM967855U87-EV human glioblastoma xenograft - Control 46.6255985
GSM967856U87-EV human glioblastoma xenograft - Control 56.3160884
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2570986
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4127986
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3975485
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2964185
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0797683
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2883485
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1781183
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2861284
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0833483